Britain and America have announced a landmark trade agreement that will guarantee zero import taxes on British medicine exports going into the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on drugs through the NHS. This pledge ensures that tariffs on these vital goods will remain at nothing for a period of the next three years.
This development is in response to earlier statements to dramatically increase duties on branded drug imports, with potential rates floated as high as 100%.
"This agreement between the United Kingdom strengthens the international landscape for cutting-edge drugs and introduces long-overdue equity to U.S.–U.K. medicine commerce," a statement noted.
Trade Significance
Drugs represent one of the UK's most significant export categories to the United States, which is easily the largest market for large British pharmaceutical firms.
Statistics indicate that in the year to the end of last September, the UK shipped medicines worth £11.1bn to the US. This value made up 17.4% of all goods exports in that timeframe.
"This guarantee protects work, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal entails several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments exceeded twenty percent.
Broader Context
This agreement follows a ongoing tension between the pharmaceutical industry and the UK government over spending levels and regulatory access.
The disagreement were exacerbated by assertions that American customers were paying several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been halted or abandoned, while substantial funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
